Stock Watch: Thoroughly Moderna Missteps
When Clinical And Regulatory Successes Fail To Impress Investors
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
